



Sygnature Discovery Overview

October 2020


Enabling Success

www.sygnaturediscovery.com

Company Overview

- Founded in 2004 at BioCity (Nottingham, UK)
- Provide high-quality, co-located, integrated drug discovery and pre-clinical resource and expertise to:
 - Major pharma companies
 - VC-backed biotechs
 - Not-for-profit organisations
- >80% of scientists have PhDs and considerable pharmaceutical industry R&D experience
- Strong track record of success for our clients:
 - 33 compounds into pre-clinical development since 2011
 - 16 compounds have advanced into the clinic (Phases I, II and III)
 - 134 client patents which have Sygnature scientists as named inventors
- Private equity-backed (Phoenix Equity Partners) since September 2017
 - Sygnature's senior management team are co-investors
 - Financially very stable
 - Investment funding acquisitions and expansion of capabilities and capacity

Company Timeline: Highlights



Source: Management information

Board of Directors

Dr Simon Hirst
Chief Executive Officer

AstraZeneca & OSI Pharmaceuticals



Dr Paul Clewlow
Senior VP, Business Development

Pharmaceutical Profiles & Argenta Discovery



Mrs Victoria Tabiner
Chief Financial Officer

Ethiprint & Tui Travel



Dr Jonathan Williams
Chief Operating Officer

Aston Molecules & OSI Pharmaceuticals



Prof Andy Black
Chairman

King's College London, MedInnovate & Kinapse



Mr Kevin Keck
Non-Executive Director

Phoenix Equity Partners



Mr Barry Robinson
Non-Executive Director

Phoenix Equity Partners



Our Characteristics



Consistent focus on delivering high quality, innovative science

- Highly-experienced teams providing problem-solving resource and intellectual input into clients' drug discovery programmes



Transparent communications with clients on project progress

- Dedicated Project / Study Leader for each research project
- Rapid identification of potential issues and possible re-design solutions
- Open dialogue to ensure agreement on best route forward for project



Excellent track record of success

- 33 compounds advance into pre-clinical development
- 16 compounds have moved into the clinic (Phases I, II and III)
- RenaSci facilitated >30 NCEs into clinical development and 10 drugs to market



Highly-motivated and well-trained staff

- Scientists recruited across the world (EU, USA, Canada, India, China, Japan and Australasia)
- Dynamic mix of youth and experience; training the next generation of drug-hunters
- Low turn-over in employees – ensures client continuity and IP security



'State-of-the-Art' Facilities

BioCity (Nottingham, UK)

- Current building occupancy:
 - Discovery Building (purpose-built 2017)
 - Laurus Building (since 2008)
 - Innovation Building (since 2018)
- 'State-of-the-art' laboratories, latest equipment to accelerate clients' research and functionally-mixed to maximise interaction between service-offerings





Alderley Park (near Manchester, UK)

- Opened new DMPK lab (Oct 2018)
- Acquisition of Alderley Oncology (May 2020)
- Plan to grow our chemistry and biology foot print in 2021

Modern, Well-Equipped Laboratories

Designed for maximal scientific interaction and integrated drug discovery



Scope of our Integrated Services

Drug Discovery -> Pre-clinical

Target Validation

- Reproducing key literature experiments to confirm isolated reports
- Demonstration of target engagements and mechanism of action

Hit Identification

- **FBDD screening**
 - SPR, MST, NMR, X-ray crystallography
 - Fragment Library
- **HTS**
 - Cellular and biochemical
- **MTS**
 - Cellular and biochemical
- **Biophysics, high-content imaging, phenotypic and radiometric assays**
- **Virtual screening**
 - Commercial & Sygnature HTC-enabled virtual libraries

Hit-to-Lead

- **Hit Validation and ADMET profiling**
- **High Throughput Chemistry (HTC)**
- **Structure-based drug discovery**
- **Fast Follower – Knowledge based approaches**
- **Ligand based – scaffold hopping (Brood, Sygnature scaffolds)**

Lead Optimisation

- **Early DMPK profiling**
 - *In vitro* and *in vivo*
- **Efficient design-make-test-analyse cycle**
- **Innovative chemistry to enable synthesis of complex target molecules**
- ***In vivo* efficacy, PK/PD and dose in man predictions**

Translational Biology

- **Biomarker validation**
 - Gene Expression, Phosphoproteins, Cytokines, Neurotransmitters, Brain Microdialysis
- ***In vivo* pharmacology**
 - Oncology
 - Immuno-oncology
 - Obesity
 - Diabetes
 - Drug abuse and addiction
 - NASH and liver disease
 - Kidney disease
 - CNS disorders
 - Rodent PK

Broad Drug Discovery Experience

- Therapeutic Areas

- Oncology
- Immuno-oncology
- Inflammation and Immunology
- Respiratory
- Neuroscience
- Anti-infectives
- Orphan diseases
- Diabetes
- Obesity
- NASH and Kidney Disease
- Drug abuse/dependence

Hit Identification

Hit-to-Lead

Lead Optimisation

Pre-clinical
Candidate

- Biological Targets

- Kinases
- GPCRs
- Epigenetic
- Ion channels
- NHRs
- Proteases
- PPIs

Why is Sygnature different?

- In-depth disease area expertise and learning:
 - 300+ scientists (>80% PhD) + significant drug discovery expertise
 - Open and positive company culture
 - Pro-active problem-solving and data interpretation to drive decision-making and project progression
- Optimally-sized for drug research project delivery to clients:
 - Integrated & co-located project teams to deliver world-class science
 - Financially stable – profits re-invested into growing the business
 - Direct and immediate local communication and interaction
- Reduced managerial overheads:
 - Integrated logistics and senior management oversight
 - Enhanced value for money by liberating internal resource within clients
- Track record of success for clients from the lab bench to the clinic:
 - 31 pre-clinical candidates
 - 16 candidate drugs in the clinic (Phases I, II and III)



An Award Winning Company



THE QUEEN'S AWARDS
FOR ENTERPRISE:
2017



1000
Europe's Fastest
Growing Companies



London
Stock Exchange Group

1000
COMPANIES TO INSPIRE
BRITAIN 2017



Winner – Best CRO 2017
Finalist – Best CRO 2019



Victoria Tabiner, CFO
Female Executive of the Year

Sygnature Group Summary

- UK-based independent provider of top quality integrated drug discovery and pre-clinical services
- Considerable scientific experience is structured to efficiently provide rapid problem solving input into clients' drug discovery and pre-clinical development projects
- Technically-advanced capabilities across a range of 'hot' therapeutic areas
- Excellent track record of success for our clients
 - Sygnature: 15 compounds in clinical studies (Phases I, II and III)
 - RenaSci: >30 NCEs into clinical development and 10 drugs on the market
- Peer level scientific collaborations which deliver drug candidates in a timely fashion





Enabling Success

www.sygnaturediscovery.com



BusDev@sygnaturediscovery.com



www.linkedin.com/company/sygnature-discovery



[@SygnatureDiscov](https://twitter.com/SygnatureDiscov)